Patent intelligence · US
US 11866515
Hemiasterlin derivatives for conjugation and therapy
Hemiasterlin derivatives for conjugation and therapy
Patent details — US 11866515
- Jurisdiction
- US
- Status
- granted
- Grant date
- Jan 9, 2024
- Expiration
- Jan 4, 2044
- Applicant
- Sutro Biopharma, Inc.
- Claims
- 12
- CPC classes
- A61K, A61K38/00, A61K47/6817, A61K47/6855
Quick answer
US 11866515 (Hemiasterlin derivatives for conjugation and therapy) is held by Sutro Biopharma, Inc.. Status: granted. Granted Jan 9, 2024. Expires Jan 4, 2044 (17 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Sutro Biopharma, Inc.
- Grant date
- Expiration
- Claims
- 12
- CPC classes
- A61K, A61K38/00, A61K47/6817, A61K47/6855, A61P, A61P35/00
More from Sutro Biopharma, Inc.
Related pharmaceutical patents in our USPTO index.
-
US 12427201
Anti-folate receptor antibody conjugates, compositions comprising anti-folate receptor antibody conjugates, and methods of making and using anti-folate receptor antibody conjugates
granted -
US 12398197
Antibodies with engineered CH2 domains, compositions thereof and methods of using the same
granted -
US 12351850
Methods of producing full-length antibodies using E. coli
granted -
US 12269801
Modified amino acids
granted -
US 12252552
Modified Fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use
granted -
US 12226490
Anti-ROR1 antibody conjugates, compositions comprising anti ROR1 antibody conjugates, and methods of making and using anti-ROR1 antibody conjugates preliminary class
granted -
US 12144869
Anti-ROR1 antibody conjugates, compositions comprising anti ROR1 antibody conjugates, and methods of making and using anti-ROR1 antibody conjugates
granted -
US 12071477
Anti-folate receptor alpha antibody conjugated with hemiasterlins
granted
Frequently asked questions
What is US patent 11866515?
US 11866515 (Hemiasterlin derivatives for conjugation and therapy) is held by Sutro Biopharma, Inc.. Status: granted. Granted Jan 9, 2024. Expires Jan 4, 2044 (17 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 11866515?
Sutro Biopharma, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 34 pharmaceutical patents for this assignee.
When does US 11866515 expire?
Our index shows an expiration date of Jan 4, 2044 (17 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.